Trials / Unknown

UnknownNCT06021912

e-ITAG Allergen Immunotherapy in the Management of Allergic Asthma

Evaluating the Efficacy of Allergen Immunotherapy in the Management of Allergic Asthma and Rhinitis

Status: Unknown
Phase: —
Study type: Observational
Enrollment: 300 (estimated)

Sponsor: General Administration of Military Health, Tunisia · Network
Sex: All
Age: 5 Years – 65 Years
Healthy volunteers: —

Summary

Allergy is defined as a specific abnormal and excessive reaction of the immune system to exposed allergen . This reaction is reproducible with each new exposure allergen . A recent study by The European Academy of Allergy and Clinical Immunology" (EAACI) estimates that 30% of the population suffers from allergic rhinitis and/or conjunctivitis, 20% of children suffer from asthma, and 8% of the population suffers from food allergies in Europe, with a clear increase in prevalence. Allergenic immunotherapy (AIT) remains a corner stone in the treatment of allergic diseases. It involves administering an increasing dose of allergens to induce immunological tolerance. The efficacy and safety of ITA have already been demonstrated. However, patient response is highly heterogeneous. This findinf illustrates the value of biomarkers in the selection of patients, enabling prediction of response to ITA and follow-up.

Detailed description

This is a prospective, observationel study conducted in Pneumology Department at the Military Hospital in collaboration with the Immunology Laboratory We followed patients in 2 groups: Group 1: patients with asthma or allergic rhinitis who had received allergen immunotherapy (AIT). Group 2: patients with asthma or allergic rhinitis who received a conventional treatment

Conditions

Study the Efficacy of ITA in Patients With Allergic Asthma or Allergic Rhinitis or Allergic Rhinitis Compared With Conventional Treatment

Interventions

Type	Name	Description
DRUG	Immunotherapy	Sublingual immunotherapy

Timeline

Start date: 2023-03-01
Primary completion: 2023-12-30
Completion: 2024-03-30
First posted: 2023-09-01
Last updated: 2023-09-01

Locations

1 site across 1 country: Tunisia

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT06021912. Inclusion in this directory is not an endorsement.